^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Abstract 5572: IMC-F106C, a novel and potent immunotherapy approach to treat PRAME expressing solid and hematologic tumors

Published date:
05/15/2020
Excerpt:
In the PRAME positive HLA-A*02:01 positive cell lines, IMC-F106C redirected donor effector cells to release IFNγ and GrB and kill tumor cells in a dose-dependent manner, with activity demonstrated as low as < 1 pM. By contrast, cell lines negative for PRAME or HLA-A*02:01 expression failed to induce responses < 1 nM of IMC-F106C.
DOI:
10.1158/1538-7445.AM2020-5572